Rayner Company Overview and History

Rayner is a leading global ophthalmic company that has been a pioneer in the development of intraocular lenses (IOLs) for over 100 years. Founded in 1914 by Sir Frank Rayner, the company has a rich history of innovation and commitment to improving eye care.

The company's early success was driven by its development of the first plastic intraocular lens, which revolutionized cataract surgery. This breakthrough marked a significant turning point in the history of ophthalmology.

Today, Rayner continues to push the boundaries of ophthalmic technology, with a product portfolio that includes a wide range of IOLs, surgical instruments, and other eye care solutions. The company's commitment to quality and innovation has earned it a reputation as a trusted partner for eye care professionals around the world.

Rayner leads the way in eye care innovation with IOLs and ophthalmic solutions designed to provide surgeons and patients with the best visual outcomes.

Sir Harold Ridley's invention of the world's first intraocular lens (IOL) in 1949 was a game-changer, and Rayner was proud to partner with him in manufacturing this groundbreaking invention.

Rayner's IOLs are now available in over 80 countries and are used by some of the leading eye surgeons around the world.

The company has been focused on providing the best visual outcomes for patients since 1910, when its first opticians opened in London.

Rayner collaborates with leading ophthalmologists throughout the world to bring about clinically superior materials and innovative new products.

Rayner's Research & Development team is dedicated to developing new products, and their mission is clear: to provide the best possible solutions for eye care.

The company's global headquarters and state-of-the-art manufacturing facility is located in Worthing on the South Coast of England.

For your interest: Perfect World (company)

Rayner has raised funding over 3 rounds, with its first funding round taking place on January 31, 2017. This round was followed by a Conventional Debt round on September 17, 2019, which raised $6.22M.

A unique perspective: Round 2 (company)

The company has 2 institutional investors, including Phoenix Equity Partners and NatWest, who participated in its latest funding round. NatWest was also involved in Rayner's earlier funding rounds, including a Conventional Debt round in 2017.

Rayner has made several investments and acquisitions in recent years, including the acquisition of This in January 2024 and Sophi in January 2024. These acquisitions were part of Rayner's strategy to drive growth and expand its offerings.

Here's a summary of Rayner's funding rounds:

Rayner is a leading ophthalmic company that has been a trusted partner for eye care professionals for over 100 years. They offer a wide range of products and services to help improve vision and eye health.

Rayner has a strong presence in the UK and Ireland, with a network of distributors and partners across the region. They also have a significant presence in other parts of the world, including Europe, the Middle East, and Asia.

Rayner's commitment to innovation is evident in their development of new products and technologies, such as their advanced intraocular lenses and surgical equipment.

In the United States, the first IOL implant was performed in 1952 at the Wills Eye Hospital in Philadelphia. It was a Ridley-Rayner lens that was implanted by surgeons Turgut Hamdi MD and Warren Reese MD, with reported good visual function results.

The first FDA-approved IOL lenses in the US were designed by Peter Choyce, a pupil of Ridley's, and manufactured by Rayner. They were the Choyce Mark VIII and Choyce Mark IX Anterior Chamber lenses, approved by the FDA in 1981.

In May 2007, the FDA approved the Rayner C-flex injectable IOL, making it a significant milestone for Rayner's products in the US market.

Rayner Surgical Inc. is an active legal entity in the US, incorporated on August 22, 2023, but its revenue and employee count are not publicly disclosed.

In the competitive market of intraocular lens technology, Rayner faces stiff competition from several established players. RxSight, a US-based company, takes the top spot with $194M in total funding, closely followed by Nayam Innovations from India with $3.26M.

One of Rayner's main competitors is Atia Vision, a US-based company that has secured $67M in funding. They specialize in presbyopia-correcting intraocular lenses. STAAR Surgical, another US-based company, also offers implantable lenses for the eye with companion delivery systems.

Rayner's position in the market is somewhat challenged by its lower Tracxn score of 59, compared to RxSight's 66. This could indicate a need for improvement in innovation and technology. Care Group, an Indian company, has a lower Tracxn score of 48, which may be a result of its unfunded status.

Here's a list of the top 5 competitors and alternates in the intraocular lens market:

Visiogen, an acquired US-based company, also offers lens technology for cataracts, but its lower Tracxn score of 37 may indicate room for improvement. HOYA Surgical Optics, a Singapore-based company, is another developer of intraocular lenses with a Tracxn score of 37.